Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 9,301–9,400 of 10,906
COVID-19 and the Heart: Lessons Learned and Future Research Directions
Lee, T. C., Omar, A. M. S., & Bella, J. N. (2024) · Cardiogenetics · doi:10.3390/cardiogenetics14010004 · Cited by 2
Oyedele, T., Park, R., Morales, K., Jain, M., Sher, L., Vutikullird, A., Isaacs, A., Jepson, B. M., Shoemaker, K., Stanley, A. M., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128304 · Cited by 3
Kipourgos, G., Kourtis, G., Papatheodorou, M., Elesnitsalis, G., Filtiseniou, P., Albani, E. N., & Tzenalis, A. (2022) · Nursing Forum · doi:10.1111/nuf.12791
Nanoparticles for Drug Delivery: Design, Mechanisms, and Clinical Translation
Jose, S. A., Crutchfield, B., Caballero, M., Carreon, E., Davis, I., & Menezes, P. L. (2026) · Molecules · doi:10.3390/molecules31173121 · Cited by 1
Considerations for unblinding individual study participants during vaccine trials
Halsey, N. A., Evans, S. J. W., Santosham, M., Hacker, A., Edwards, K. M., Chandler, R. E., Dudley, M. Z., Dekker, C. L., Al-Abri, S., Arora, N. K., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.04.033 · Cited by 1
Sedaghat, M., Karami, B., Najafi, F., Shadmani, F. K., & Rezaeian, S. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126424 · Cited by 2
Harwood, C. A., & Sterling, J. C. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook025 · Cited by 1
van der Heiden, M., Shetty, S. A., Bijvank, E., Beckers, L., Çevirgel, A., van Sleen, Y., Tcherniaeva, I., Ollinger, T., Burny, W., van Binnendijk, R. S., et al. (2024) · medRxiv · doi:10.1101/2024.01.22.24301601 · Cited by 1
Side effects of COVID-19 vaccination in Pakistani population: A cross sectional study
Ain, Q., Khan, M., Afrah, A., Akmal, Z., Javed, S., Nawaz, A., Khan, M. I., & Sadiq, F. (2024) · Bangladesh Journal of Medical Science · doi:10.3329/bjms.v23i2.66233 · Cited by 1
COVID-19 vaccine utilizing the technology of gene therapy
中神, 啓., & 森下, 竜. (2022) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.59.34 · Cited by 1
Song, Q., Liu, H., Tan, H., et al. (2024) · Journal of Global Health · doi:10.7189/jogh.14.05015 · Cited by 1
Engineered Migrasomes: A Robust, Thermally Stable Vaccination PlatformPreprint
Wang, D., Wang, H., Wan, W., Zhu, Z., Sho, T., Zheng, Y., Zhang, X., Dou, L., Ding, Q., Yu, L., et al. (2024) · eLife · doi:10.7554/elife.97621.1 · Cited by 4
Black, B. S., & Thaw, D. B. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4659854 · Cited by 1
Patterns of restricted TCR usage following SARS-CoV-2 vaccination and severe disease
Parsons, E. L., Lu, Z., Richard, S. A., Zelkoski, A. E., Le, J., Palanikumar, N., Nguyen, P., Alba, C., Sukumar, G., Rosenberger, J. G., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1576903 · Cited by 1
Thoo, L., Gumowski, P. I., Kammermann, K., Nussli, S., Grabscheid, B., Hausmann, O. V., Axius, U., Pichler, W. J., & Yerly, D. (2021) · Swiss Medical Weekly · doi:10.4414/smw.2021.w30005 · Cited by 1
Evaluation of serum and cerebrospinal fluid biomarkers after vaccination against SARS‐CoV ‐2
Iacono, S., Piccoli, T., Aridon, P., Schirò, G., Blandino, V., Tarantino, D., Agnello, L., Ciaccio, M., Ragonese, P., & Salemi, G. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51785 · Cited by 1
Carnero, M., Cuerpo, G., Menéndez, J. L., et al. (2023) · Cirugía Cardiovascular · doi:10.1016/j.circv.2023.04.003 · Cited by 1
Nikitina, V. A., Laurini, G. S., Montanaro, N., & Motola, D. (2023) · Acta Paediatrica · doi:10.1111/apa.16954 · Cited by 1
Martín‐Sánchez, E., Tamariz‐Amador, L., Guerrero, C., Zherniakova, A., Zabaleta, A., Maia, C., Blanco, L., Alignani, D., Fortuño, M.-A., Grande, C., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01089-5 · Cited by 2
Quinn, M. A., Parra-Rodriguez, L., Alsoussi, W. B., Ayres, C., Klebert, M. K., Liu, C., Suessen, T., Scheaffer, S. M., Middleton, W. D., Teefey, S. A., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200920 · Cited by 1
Xu, Y., Kong, X., Huang, W., Liang, Z., Huang, J., Li, Y., Zhang, N., Liu, D., Guo, W., & Mei, J. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2307504 · Cited by 2
Bracke, C., Miranda, C., González, S. M., Casas, I., Cardona, P.-J., Benítez, R. M., Sopena, N., Reynaga, E. A., Massanella, M., Clotet, B., et al. (2022) · Pathogens · doi:10.3390/pathogens11111364 · Cited by 2
Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours
Yuile, A., Wei, J., McKelvey, K. J., Colvin, E. K., Zakarya, R., Stoner, S. P., Jagadeesan, A., Yunus, M., de Silva, H. C., Gilson, J., et al. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05258-9 · Cited by 1
“Opportunistically, the COVID-19 pandemic accelerated the development and global rollout of mRNA (BNT162b2, mRNA-1273) and adenoviral DNA-based (ChAdOx1) vaccines [15, 16], which use similar platforms as cancer vaccines.”
Bello, U. L., Ja’afar, I. K., Ogbolosingha, A. J., Isa, A., Muhammad, J. H., & Abubakar, A. H. (2024) · Alexandria Journal of Medicine · doi:10.1080/20905068.2024.2317030 · Cited by 2
Pimenta, P. D. C., Lima, T. C. D. A., Geraldine, V. G. S., Tourinho, F. S., do Nascimento, M. C., Novaes, R. D., & Paranaiba, L. M. R. (2025) · American Journal of Health Promotion · doi:10.1177/08901171251365229 · Cited by 5
mRNA cancer vaccine: A novel and potential immunotherapy for multiple myeloma
Feng, Y., Du, Y., Zhang, C.-T., Xie, F., & Yan, J. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189493 · Cited by 2
A metabolic boost to mRNA vaccines
Chada, N. C., & Wilson, J. T. (2026) · Nature Materials · doi:10.1038/s41563-026-02628-0 · Cited by 1
The Second Wave of COVID-19: Challenges and Preparations
Mohan, A. (2022) · The Indian Journal of Chest Diseases and Allied Sciences · doi:10.5005/ijcdas-63-3-123 · Cited by 1
Criteria for judging the immune markers of COVID‐19 disease vaccines
Lin, N., Fu, H., Pu, D., Quan, Y., Li, Y., Yin, X., Wei, Y., Wang, H., Ma, X., & Wei, X. (2021) · MedComm · doi:10.1002/mco2.109
Modular design of dual-targeted, enzyme-responsive peptide carriers for gene drug delivery
Jiao, X., Han, M., Wang, Z., Min, J., Su, R., Tie, H., Qi, W., & Wang, Y. (2026) · Nanoscale Horizons · doi:10.1039/d5nh00803d · Cited by 1
Cui, Z., Luo, Y. Q., Yi, Y., et al. (2025) · Immunological Medicine · doi:10.1080/25785826.2025.2528331 · Cited by 1
“As the internationally recognized most effective means to prevent SARS-CoV-2, COVID-19 vaccines have been proven safe and effective by the vast majority of experiments [3–6].”
COVID-19 vaccination atlas: an integrative systems vaccinology approachPreprint
Prates-Syed, W. A., Fonseca, D. L. M., Pour, S. Z., Schimke, L. F., Lira, A. A. D. L., Côrtes, N., Silva, J. D. Q., Carvalho, E., Filgueiras, I. S., Vinces, T. G. C., et al. (2024) · medRxiv · doi:10.1101/2024.05.22.24307755 · Cited by 1
Stark, F. C., Akache, B., Deschatelets, L., Tran, A., Stuible, M., Durocher, Y., McCluskie, M. J., Agbayani, G., Dudani, R., Harrison, B. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.02.482651 · Cited by 1
Dueker, K., Capozzola, T., Feng, Z., Lin, R. N., Hurtado, J., Bangaru, S., Yuan, M., Beutler, N., Garcia, E., He, W.-T., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117439 · Cited by 3
Marineci, C. D., Valeanu, A., Negreș, S., & Chiriţă, C. (2021) · Farmacist ro · doi:10.26416/farm.198.1.2021.4353 · Cited by 1
Vaccines After an Emergency Use Authorization (EUA): Modern Evidence Generation Approaches
Zariffa, N. M.-D., & Russek‐Cohen, E. (2021) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-021-00290-z · Cited by 1
Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives
Yang, M., Song, Y., Wang, Z., Chao, K., Li, L., Zhang, X., Duan, X., Yu, C., Xue, R., & Zhao, J. (2026) · MedComm · doi:10.1002/mco2.70791 · Cited by 5
Key points to keep in mind related to COVID-19 vaccines in people with multiple sclerosis
Galleguillos, L., & Alonso, R. N. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103142 · Cited by 2
Yıldız, R., & Nişancı, O. S. (2025) · The Turkish Journal of Geriatrics · doi:10.29400/tjgeri.2025.454 · Cited by 1
Alves, K., Kotloff, K., McClelland, R. S., Hammershaimb, E. A., Kouassi, A., Plested, J. S., Kalkeri, R., Zhu, M., Cloney-Clark, S., Cai, Z., et al. (2025) · Vaccine X · doi:10.1016/j.jvacx.2025.100728 · Cited by 1
Self-citationHerpetic Eye Disease During the COVID-19 Pandemic at an Urban Hospital System
Song, A., Lin, L., & Lobo-Chan, A.-M. (2025) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2025.2508405
Schmidt, T., Trilling, M., Le‐Trilling, V. T. K., Asar, L., Fiedler, M., Oster, C., Grieger, J., Cappello, G., Kizina, K., Grzib, L., et al. (2026) · Cancers · doi:10.3390/cancers18030494
“Since their introduction, COVID-19 vaccines have been very safe and highly effective in reducing transmission, hospitalizations, and mortality [1–6].”
Rogers, Z. J. (2023) · Digital Repository Service (Northeastern University) · doi:10.17760/d20621546
Eom, T., Seong, K., Kim, S. H., Kim, S., & Yang, S. Y. (2026) · Macromolecular Research · doi:10.1007/s13233-026-00544-5
Mukenge, E. K., Sumbu, B. M.-M., Nkodila, A. N., Muwonga, J. M., Makulo, J. R. R., Ngole, M. Z., Bepouka, B. I., Longokolo, M. M., Kamwiziku, G. K., Situakibanza, H. N.-T., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10754-4
“%) effective in preventing symptomatic infection with onset at least 14 days after the second dose [9].”
Implication de l'axe C5a-C5aR1 dans l'orage inflammatoire des formes sévères de COVID-19 de l'adulte
Carvelli, J. (2023) · theses.fr (ABES) · doi:10.70675/be12640bzc919z4322zb146z5a584bd7ec67
Khan, M. I., Sankaran, K. R., & Rahaman, S. O. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.13.705811
Antibody testing as the guide to our living with COVID-19
Kaku, N., Nakagama, Y., Nitahara, Y., & Kido, Y. (2022) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.33.338
РЕАЛІЗАЦІЯ СОЦІАЛЬНОЇ ФУНКЦІЇ У КОМЕРЦІЙНІЙ ПРИРОДІ ГЛОБАЛЬНОГО ФАРМАЦЕВТИЧНОГО РИНКУ
Мовсесян, А. (2024) · Економіка та суспільство · doi:10.32782/2524-0072/2024-67-159
Dimitrov, G., Kalinov, K., & Valkov, T. (2024) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2024.2359003
Kiryukhin, A. I., Игоревна, Т. Е., Popova, L. L., & Konstantinov, D. Y. (2023) · Bulletin of the Medical Institute REAVIZ (REHABILITATION DOCTOR AND HEALTH) · doi:10.20340/vmi-rvz.2023.3.covid.2
Tranchito, E. N., Goslawski, A. M., Cabrera, C. I., Rabbani, C. C., Fowler, N., Li, S., Thuener, J. E., Lavertu, P., Rezaee, R. P., Teknos, T. N., et al. (2022) · Encyclopedia · doi:10.3390/encyclopedia2040133 · Cited by 1
Basic Research Reveals the Unique Virologic Features of SARS-CoV-2
Uraki, R., Yamayoshi, S., & Kawaoka, Y. (2021) · TRENDS IN THE SCIENCES · doi:10.5363/tits.26.9_79
Stamm, C. E., Zhu, J., Davis-Vargas, C., Dirasantha, O., Thankamani, K., & Rao, V. B. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.28.702426
González, C. P. V., Vahos, J., Páez, S., Páez, M., & José Julián López, G. (2024) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v72n2.111722
Gold, M. J., Millar, D. G., Liu, J., Menon, H., Karpov, Y., Olsen, K., Oliveira, L. T., Dubé, C., Tran, C. W., Elford, A. R., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103076
Dumas, P., Bertoli, S., Bonmati, C., et al. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106901
Hunziker, P. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3794249
Bosinger, S. E., Edwards, C. T., Karunakaran, K. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.30.605768
MicroRNAs in Penile Cancer: A Systematic Review of Diagnostic, Prognostic, and Mechanistic Evidence
Zhang, X., Rahman, F., Kelly, J. D., et al. (2026) · European Urology Focus · doi:10.1016/j.euf.2026.06.028
Pre-vaccine sentinel antibodies predict blunted vaccine responses
Song, L.-S., Park, J. G., Qiu, J., Murugan, V., mousavi, S., Hou, C.-W., Magee, D. M., Chen, Z., Chung, Y., Williams, S., et al. (2026) · Cell press blue · doi:10.1016/j.cpblue.2026.100088
Bene, A. D., D’Aniello, A., Mottola, S., Mazzarella, V., Cutolo, R., Campagna, E., Benedetti, R., Altucci, L., Cosconati, S., Maro, S. D., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00032g
Mohapatra, R. K., Seidel, V., Kandi, V., & Rabaan, A. A. (2023) · Frontiers research topics · doi:10.3389/978-2-8325-3603-2
Does COVID-19 Vaccination Protect Contact Persons? A Systematic Review
Kampf, G. (2024) · Hygiene · doi:10.3390/hygiene4010003 · Cited by 1
Garrett, N., Tapley, A., Hudson, A., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4890648
Self-citationNanomedicines and nanovaccines manufacturing
Mahaling, B., Baruah, N., Manthripragada, P., & Dinabandhu, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44579-8.00023-0
Possibilities and principles of vaccination against COVID-19
Křupka, M., Kosztyu, P., Racanský, M., Schovánek, J., Sloupenská, K., Strojil, J., & Raška, M. (2021) · Praktické lékárenství · doi:10.36290/lek.2021.001 · Cited by 1
Comparisons Of Mrna Vaccine from Different Manufactures
Wang, Y., & Zou, X. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v45i.7392
Улюкин, И. М., Рассохин, В. В., Сечин, А. А., & Орлова, Е. С. (2024) · HIV Infection and Immunosuppressive Disorders · doi:10.22328/2077-9828-2024-16-3-25-35
Sanfilippo, G. L., Badami, G. D., Manna, M. P. L., Pizzo, M., Lio, D., Giammanco, A., & Caccamo, N. (2026) · Biomolecules · doi:10.3390/biom16081111
“The most widely used formulations contain a modified messenger RNA sequence encoding the virus’s Spike protein [2].”
Chemotherapy and COVID-19 Vaccination in Patients With Gastrointestinal Cancer
Suenaga, M., Yamauchi, S., Morikawa, R., et al. (2024) · In Vivo · doi:10.21873/invivo.13566
Causation and Classification of Disease
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0005
Prévention des infections et vaccination dans les rhumatismes inflammatoires chroniques
Morel, J. (2022) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2022.07.004
Rottenstreich, A., Zarbiv, G., Oiknine‐Djian, E., Vorontsov, O. M., Zigron, R., Kleinstern, G., Wolf, D. G., & Porat, S. (2021) · medRxiv · doi:10.1101/2021.08.30.21262875
The pharmaceutical market: a transdisciplinary description of concepts and their implications
Motta-Santos, A. S., Noronha, K., Ribeiro, L. C., Gow, J., Alam, K., & Andrade, M. V. (2026) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2026.2613683 · Cited by 1
“Recent experiences have demonstrated the ability of the pharmaceutical industry to create innovative solutions effectively and quickly when all stakeholders align their objectives (as seen during the COVID-19 pandemic) [37–39].”
Strategies of HIV-1 Vaccines Based on mRNA Platforms
Liu, P. C., Zhong-Yue, F. A. N. G., Chen, X., Shao-Wei, L. I., & Ying, G. U. (2026) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS · doi:10.3724/j.pibb.2025.0511
COVID-19 Vaccines – What are Known? What are not yet known?
Loh, J., & Yew, W. S. (2021) · The Singapore Family Physician · doi:10.33591/sfp.47.7.uo2
Rule Based Mamdani Fuzzy Inference System to Analyze Efficacy of COVID19 Vaccines
Mittal, P. C., Abirami, S. P., Ramya, P., Balajee, J. M., & Muniyandy, E. (2024) · EAI Endorsed Transactions on Pervasive Health and Technology · doi:10.4108/eetpht.10.5571
Miran, C., Bonnet, É., Allignet, B., et al. (2021) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2021.03.005
COVID-19 – One Virus, One World But Different Vaccines and ShotsPreprint
Sok, P. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3925477
Noguchi, K. S., Nguyen, L., Mehdipour, A., Wiley, E., Saunders, S., Moncion, K., Reid, J. C., Bakaa, N., Díaz, L. G., Damme, J. V., et al. (2022) · Frontiers in Rehabilitation Sciences · doi:10.3389/fresc.2022.881606 · Cited by 1
Ünal, S., Gürsoy, M., & Pasin, O. (2025) · The Anatolian Journal of General Medical Research · doi:10.4274/anatoljmed.2025.74946
mRNA-1273-SARS-CoV-2-Impfstoff
(2021) · Allgemein- und Viszeralchirurgie up2date · doi:10.1055/a-1540-2379
Barrett, E. G., Revelli, D., Bakshi, C. S., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1212179
Ishikawa, U., Mabrouk, M. T., & Yang, Y. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.5c00166
SARS-CoV-2 infection in lung transplant recipients: a single-center retrospective study in Japan
Kohno, M., Ohsumi, A., Kimura, J., et al. (2025) · Surgery Today · doi:10.1007/s00595-025-03136-5
The Variance-Stabilizing Transformation for the Poisson Rate Ratio: Closed-Form Confidence IntervalsPreprint
Ng, S.-P. (2026) · medRxiv · doi:10.64898/2026.07.16.26358255
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.